These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 20419463)
21. Adalimumab: a review of its use in adult patients with rheumatoid arthritis. Cvetković RS; Scott LJ BioDrugs; 2006; 20(5):293-311. PubMed ID: 17025376 [TBL] [Abstract][Full Text] [Related]
22. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Li S; Kaur PP; Chan V; Berney S Clin Rheumatol; 2009 Jul; 28(7):787-91. PubMed ID: 19291350 [TBL] [Abstract][Full Text] [Related]
23. Tuberculous pleurisy diagnosed by medical thoracoscopy in an adalimumab-treated rheumatoid arthritis patient after treatment of latent tuberculosis infection. Nagafuchi Y; Shoda H; Fujio K; Ishii S; Sugiyama H; Yamamoto K Mod Rheumatol; 2013 Sep; 23(5):1013-7. PubMed ID: 22911136 [TBL] [Abstract][Full Text] [Related]
24. Cerebral tuberculoma and magnetic resonance imaging. Helmy A; Antoun N; Hutchinson P J R Soc Med; 2011 Jul; 104(7):299-301. PubMed ID: 21725096 [No Abstract] [Full Text] [Related]
25. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471 [TBL] [Abstract][Full Text] [Related]
26. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Tubach F; Salmon D; Ravaud P; Allanore Y; Goupille P; Bréban M; Pallot-Prades B; Pouplin S; Sacchi A; Chichemanian RM; Bretagne S; Emilie D; Lemann M; Lortholary O; Mariette X; Arthritis Rheum; 2009 Jul; 60(7):1884-94. PubMed ID: 19565495 [TBL] [Abstract][Full Text] [Related]
27. Adalimumab: a review of its use in rheumatoid arthritis. Bang LM; Keating GM BioDrugs; 2004; 18(2):121-39. PubMed ID: 15046527 [TBL] [Abstract][Full Text] [Related]
28. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. Titos Arcos JC; Hallal H; Robles M; Andrade RJ Rev Esp Enferm Dig; 2012 May; 104(5):282-4. PubMed ID: 22662786 [No Abstract] [Full Text] [Related]
29. A rare third ventricle solitary tuberculoma. N'da HA; Haidara A; Drogba L; Derou LK; Yao SK; Ba Zézé V Pan Afr Med J; 2013; 16():5. PubMed ID: 24570776 [TBL] [Abstract][Full Text] [Related]
31. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Mease PJ Expert Opin Biol Ther; 2005 Nov; 5(11):1491-504. PubMed ID: 16255652 [TBL] [Abstract][Full Text] [Related]
32. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy. Nagashima T; Minota S J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792 [No Abstract] [Full Text] [Related]
33. Necrotizing group A streptococcal periorbital infection following adalimumab therapy for rheumatoid arthritis. Roos JC; René C; Ostor AJ Cutan Ocul Toxicol; 2011 Jun; 30(2):160-2. PubMed ID: 21077727 [TBL] [Abstract][Full Text] [Related]
34. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139 [TBL] [Abstract][Full Text] [Related]
35. Radiologic observation: repair of focal bone erosions after humanized antitumor necrosis factor antibody adalimumab therapy in a patient with rheumatoid arthritis. Ahn IE; Ju JH; Park SH; Kim HY Clin Rheumatol; 2010 Feb; 29(2):211-3. PubMed ID: 19809777 [TBL] [Abstract][Full Text] [Related]
36. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278 [TBL] [Abstract][Full Text] [Related]
37. Adalimumab-induced neutropenia in a patient with rheumatoid arthritis. Ottaviani S; Cerf-Payrastre I; Kemiche F; Pertuiset E Joint Bone Spine; 2009 May; 76(3):312-3. PubMed ID: 19289296 [No Abstract] [Full Text] [Related]
38. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409 [TBL] [Abstract][Full Text] [Related]
39. Successful use of adalimumab for treating rheumatoid arthritis with autoimmune sensorineural hearing loss: two birds with one stone. Morovic Vergles J; Radic M; Kovacic J; Salamon L J Rheumatol; 2010 May; 37(5):1080-1. PubMed ID: 20439536 [No Abstract] [Full Text] [Related]
40. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]